Question 1

What is combined oxidative phosphorylation defect type 4?

Accepted Answer

Combined oxidative phosphorylation defect type 4 is a rare mitochondrial disorder that affects energy production in multiple organ systems. It is caused by pathogenic variants in the TUFM gene, which impair mitochondrial protein synthesis. Affected infants typically present in the neonatal period with severe metabolic acidosis, respiratory distress, and lactic acidosis, and the condition is very rare, affecting fewer than 1 in 1,000,000 people. The early onset and multisystem involvement underscore the serious nature of this disorder.

Question 2

What are the symptoms of combined oxidative phosphorylation defect type 4?

Accepted Answer

Infants with combined oxidative phosphorylation defect type 4 often present with severe metabolic acidosis and respiratory distress shortly after birth. They experience persistent lactic acidosis and episodes of metabolic crises that can lead to marked neurodevelopmental challenges. Clinical features include developmental regression, microcephaly, abnormal gaze fixation and pursuit, axial hypotonia accompanied by limb spasticity, and reduced spontaneous movements. Neuroimaging typically reveals polymicrogyria, white matter abnormalities, multiple cystic brain lesions (including those in the basal ganglia), and cerebral atrophy. Not all individuals experience all of these features, and severity varies considerably.

Question 3

What causes combined oxidative phosphorylation defect type 4?

Accepted Answer

Combined oxidative phosphorylation defect type 4 arises from pathogenic variants in the TUFM gene, which encodes a protein essential for mitochondrial protein synthesis. The resulting disruption in the energy production pathway is responsible for the severe metabolic abnormalities observed in affected infants. This condition is inherited in an autosomal recessive pattern, which means that an affected child inherits one mutated copy of the gene from each parent. It is more common when parents share a common ancestor, as this increases the likelihood of both being carriers; genetic counseling is recommended to help families understand these risks. Associated genes include TUFM.

Question 4

How is combined oxidative phosphorylation defect type 4 inherited?

Accepted Answer

combined oxidative phosphorylation defect type 4 follows an autosomal recessive inheritance pattern. This means a child must inherit a copy of the altered gene from both parents to develop the condition. Parents who each carry one copy typically do not show symptoms.

Question 5

How rare is combined oxidative phosphorylation defect type 4?

Accepted Answer

combined oxidative phosphorylation defect type 4 is classified as very rare. The estimated prevalence is approximately <1 in 1,000,000. Because rare disease data can be limited, actual numbers may differ from published estimates.

Question 6

How is combined oxidative phosphorylation defect type 4 diagnosed?

Accepted Answer

Diagnosis is confirmed through molecular genetic testing that identifies pathogenic variants in TUFM. In addition to genetic testing, clinical evaluation plays an important role and may include assessment of metabolic biomarkers such as persistent lactic acidosis and neuroimaging studies that reveal characteristic brain abnormalities. Because symptoms can overlap with those of other metabolic or mitochondrial disorders, definitive diagnosis relies on genetic confirmation.

Question 7

Are there treatments for combined oxidative phosphorylation defect type 4?

Accepted Answer

Currently, management focuses on supportive care and symptom management, as there are no treatments officially linked to this condition. A multidisciplinary team typically addresses the metabolic disturbances, respiratory challenges, and neurological complications, tailoring interventions to each individual’s needs. Genetic counseling is advised to help families understand the condition and explore management options, and patients should discuss treatment options with their healthcare team to determine which supportive measures may be most appropriate for their situation.

Question 8

What complications can arise from combined oxidative phosphorylation defect type 4?

Accepted Answer

Complications from combined oxidative phosphorylation defect type 4 can include severe metabolic crises, respiratory distress, and neurodevelopmental challenges. Infants may experience developmental regression, microcephaly, and abnormal muscle tone, which can affect their daily activities. These complications can vary widely among individuals, making it important for families to work closely with healthcare providers to monitor and manage these issues.

Question 9

How does combined oxidative phosphorylation defect type 4 affect daily life for patients and families?

Accepted Answer

Living with combined oxidative phosphorylation defect type 4 can be challenging for both patients and their families. Infants may require ongoing medical care, including management of metabolic disturbances and respiratory support. Families often need to adapt their daily routines to accommodate medical appointments and therapies, and they may benefit from support groups to connect with others facing similar challenges.

Question 10

What is the prognosis for individuals with combined oxidative phosphorylation defect type 4?

Accepted Answer

The prognosis for individuals with combined oxidative phosphorylation defect type 4 can vary significantly. Many affected individuals face serious challenges from early infancy, including metabolic disturbances and neurodevelopmental difficulties. While some may stabilize over time, others may experience further decline, so ongoing care and support are essential for managing their health.

Question 11

What specialists should families consult for managing combined oxidative phosphorylation defect type 4?

Accepted Answer

Families managing combined oxidative phosphorylation defect type 4 should consult a multidisciplinary team of specialists. This team may include geneticists, metabolic specialists, neurologists, and respiratory therapists to address the various challenges associated with the condition. Working with these specialists can help ensure that patients receive comprehensive care tailored to their specific needs.

Organ System	Phenotype Count	Example Features
Brain and nerves	3	Encephalopathy, Loss of previously acquired skills (developmental regression), Spasticity

Research Type	Count	% of Total
Laboratory research	22	46%

Kisho

combined oxidative phosphorylation defect type 4

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Explore clinical features

Recent Publications

combined oxidative phosphorylation defect type 4

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is combined oxidative phosphorylation defect type 4?

What are the symptoms of combined oxidative phosphorylation defect type 4?

What causes combined oxidative phosphorylation defect type 4?

How is combined oxidative phosphorylation defect type 4 inherited?

How rare is combined oxidative phosphorylation defect type 4?

How is combined oxidative phosphorylation defect type 4 diagnosed?

Are there treatments for combined oxidative phosphorylation defect type 4?

What complications can arise from combined oxidative phosphorylation defect type 4?

How does combined oxidative phosphorylation defect type 4 affect daily life for patients and families?

What is the prognosis for individuals with combined oxidative phosphorylation defect type 4?

What specialists should families consult for managing combined oxidative phosphorylation defect type 4?

Explore clinical features

Recent Publications